Five new reads converge on the same message: synthetic data is scaling fast—especially via LLMs—but evaluation, provenance, and accountability are lagging behind. For regulated domains, “can we generate it?” is being replaced by “can we defend it?”
A Scoping Review of Synthetic Data Generation by Language Models in Biomedical Research
An arXiv scoping review surveyed 59 biomedical studies (2020–2025) using LLMs for synthetic data generation. Prompt-based generation dominated (74.6%), but the paper reports heterogeneous evaluation practices across clinical research domains. The result is a fragmented evidence base: teams are generating data quickly, but measuring utility, privacy, and bias in inconsistent ways that are hard to compare or audit.
- Data leads should expect reviewers and IRBs to ask for clearer, standardized evaluation—not just “it looks realistic.”
- Prompt-based pipelines are operationally easy, but reproducibility and change control become governance issues.
- Vendor/model accessibility constraints can dictate what synthetic approaches are feasible in clinical settings.
Synthetic Data: The New Data Frontier
The World Economic Forum published a synthetic data report positioning it as a strategic tool for data scarcity, privacy protection, and AI training, alongside governance recommendations for developers, organizations, and policy-makers. This is not a technical spec; it’s institutional signaling that synthetic data is becoming part of the responsible-AI policy toolkit. For founders, it’s also a hint at where procurement checklists may go next: documentation, controls, and accountability.
- Expect more “synthetic data governance” language in enterprise RFPs and regulatory discussions.
- Compliance teams can map synthetic workflows to existing controls (risk assessment, audit trails, access management).
Synthetic Data in Health Economics and Outcomes Research
A PubMed-indexed article describes synthetic data use in health economics and outcomes research, including improving data availability and privacy protection and strengthening findings for underrepresented populations in rare disease studies. The emphasis on rare disease and underrepresented cohorts is a practical reminder: synthetic data is often used to reduce sparsity, but that can amplify modeling assumptions. The paper also calls for standardized evaluation frameworks—echoing the broader governance gap.
- Equity claims require evidence: teams need subgroup-level utility and bias checks, not only aggregate metrics.
- Privacy protection should be demonstrated with repeatable tests and clear reporting, not implied by “synthetic.”
SynthLLM: Breaking the AI “Data Wall” with Scalable Synthetic Data
Microsoft Research Asia introduced SynthLLM, a framework for generating synthetic training data from pretraining corpora, targeting multiple domains including healthcare, autonomous driving, education, and code generation. The framing is infrastructure: scaling data creation to push past the “data wall.” For practitioners, the operational questions shift to provenance (what corpora), quality assurance, and where synthetic data fits into training mixes without silently importing bias or policy violations.
- Provenance and documentation become first-class artifacts when synthetic data is derived from pretraining corpora.
- Teams will need QA gates (schema checks, distribution checks, leakage tests) as synthetic generation scales.
GenAI Synthetic Data Create Ethical Challenges for Scientists
A PNAS article examines ethical issues when scientists use generative AI tools (including ChatGPT, Copilot, DALL-E-3, and Stable Diffusion) to create synthetic data for research. The focus is accountability: who is responsible when synthetic data introduces errors, bias, or misleading evidence into the scientific record? For institutions, this is a policy design problem—defining acceptable use, disclosure norms, and review requirements.
- Research governance will likely require disclosure of synthetic generation methods and toolchains.
- Labs and companies need clear ownership of failure modes: model provider vs. user vs. institution.
- Ethical guidance is converging on documentation and review, not blanket bans.